Hans Schleussner (†2015) founded 1946 together with his father Carl Adolf Schleussner (†1959) the "Biotest-Serum-Institut GmbH" in Frankfurt, Main, Germany. In the beginning, Biotest focused on the research and production of test sera for blood grouping. The Biotest-Serum-Institut GmbH, was located in Villa Manskopf in Frankfurt Niederrad since 1956, had in the meantime developed into a pioneering company in research and production in the fields of immunology, hematology and transfusion medicine. In 1960, the new plant was built in Dreieich, where production also began in 1962 and where the company is still headquartered today.
In 1986, Hans Schleussner converted the former "Biotest-Serum-Institut GmbH" into a stock corporation. From 1986 to 1996, he headed "Biotest AG" as Chairman of the Management Board. He then moved to its Supervisory Board, where he served as Chairman from 1996 to 2002, then as Honorary Chairman.
After her marriage, Renate Schleussner (born Krumm, † 2021) worked in Biotest as a member of the Advisory Board (1986-2000) and the Supervisory Board (1987-2001). The married couple have two children - Martin and Cathrin Schleussner. Cathrin Schleussner was a member of the Supervisory Board of "Biotest AG" since 2001 and held the position of Deputy Chairman from 2004 until the takeover by the Chinese "Creat Group" in 2018.
Biotest established the Renate & Hans Schleussner Biotest Award, with the aim to identify, promote and support the realization of innovative clinical and scientific work that offers a greater insight into viral infection treatment with hyper-immunoglobulins.
Biotest wants to focus the support to the interaction of viral infections with the immune system in a highly interesting area by fostering activities in this area with access to Biotest grants.
Beginning with 2021 onwards we are pleased to support new and promising research proposals in the important area of immunological viral treatments with the Renate & Hans Schleussner Award.
The Renate & Hans Schleussner Award aims to promote the realization of innovative ideas and visions in the field of virus immune system interaction. The program will support individual projects of no more than 50,000 € each. It is Biotest’s intent to support one well-defined clinical or preclinical project.
For each award cycle there will be a selected focus, this year it is the prevention or treatment of viral infections with hyper immunoglobulins.
About Biotest AG
Biotest is a supplier of plasma proteins and biotherapeutic drugs. With a value chain that extends from pre-clinical and clinical development to worldwide marketing, Biotest specializes primarily in the application areas of clinical immunology, hematology and intensive care and emergency medicine.
Biotest develops and markets immunoglobulins, coagulation factors and albumin, which are produced on the basis of human blood plasma and are used in diseases of the immune system or haematopoietic systems. Biotest employs more than 1,900 people worldwide. The ordinary and preference shares of Biotest AG are listed in the Prime Standard of the German Stock Exchange.
More details about Biotest you will find here